Ovarian cysts during tamoxifen use may affect the prognostic markers of premenopausal breast cancer

References

• Mouridsen H, Giobbie-Hurder A, Goldhirsch A, Thürlimann B, Paridaens R, Smith I, Mauriac L, et al.; BIG 1-98 Collaborative Group. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med 2009;361:766–776.
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687–1717.
   Google Scholar
• Ismail SM. Gynaecological effects of tamoxifen. J Clin Pathol 1999;52:83–88.
   PubMed Web of Science ®Google Scholar
• Partridge AH, Wang PS, Winer EP, Avorn J. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 2003;21:602–606.
   PubMed Web of Science ®Google Scholar
• Metindir J, Aslan S, Bilir G. Ovarian cyst formation in patients using tamoxifen for breast cancer. Jpn J Clin Oncol 2005;35:607–611.
   PubMedGoogle Scholar
• Mourits MJ, de Vries EG, Willemse PH, ten Hoor KA, Hollema H, Sluiter WJ, de Bruijn HW, van der Zee AG. Ovarian cysts in women receiving tamoxifen for breast cancer. Br J Cancer 1999;79:1761–1764.
   PubMed Web of Science ®Google Scholar
• Rock CL, Flatt SW, Laughlin GA, Gold EB, Thomson CA, Natarajan L, Jones LA, et al.; Women’s Healthy Eating and Living Study Group. Reproductive steroid hormones and recurrence-free survival in women with a history of breast cancer. Cancer Epidemiol Biomarkers Prev 2008;17:614–620.
   PubMed Web of Science ®Google Scholar
• Cheung KL, Graves CR, Robertson JF. Tumour marker measurements in the diagnosis and monitoring of breast cancer. Cancer Treat Rev 2000;26:91–102.
   Google Scholar
• Molina R, Jo J, Filella X, Zanon G, Pahisa J, Mu noz M, Farrus B, et al. c-erbB-2 oncoprotein, CEA, and CA 15.3 in patients with breast cancer: prognostic value. Breast Cancer Res Treat 1998;51:109–119.
   PubMed Web of Science ®Google Scholar
• Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998;351:1393–1396.
   PubMed Web of Science ®Google Scholar
• Krajcik RA, Borofsky ND, Massardo S, Orentreich N. Insulin-like growth factor I (IGF-I), IGF-binding proteins, and breast cancer. Cancer Epidemiol Biomarkers Prev 2002;11:1566–1573.
   PubMed Web of Science ®Google Scholar
• Renehan AG, Zwahlen M, Minder C, O’Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 2004;363:1346–1353.
   PubMed Web of Science ®Google Scholar
• Schernhammer ES, Holly JM, Pollak MN, Hankinson SE. Circulating levels of insulin-like growth factors, their binding proteins, and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2005;14:699–704.
   PubMed Web of Science ®Google Scholar
• Vadgama JV, Wu Y, Datta G, Khan H, Chillar R. Plasma insulin-like growth factor-I and serum IGF-binding protein 3 can be associated with the progression of breast cancer, and predict the risk of recurrence and the probability of survival in African-American and Hispanic women. Oncology 1999;57:330–340.
   PubMedGoogle Scholar
• Han W, Nicolau M, Noh DY, Jeffrey SS. Characterization of molecular subtypes of Korean breast cancer: an ethnically and clinically distinct population. Int J Oncol 2010;37:51–59.
   PubMedGoogle Scholar
• Thürlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, et al.; Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005;353:2747–2757.
   PubMed Web of Science ®Google Scholar
• Grunfeld EA, Hunter MS, Sikka P, Mittal S. Adherence beliefs among breast cancer patients taking tamoxifen. Patient Educ Couns 2005;59:97–102.
   PubMed Web of Science ®Google Scholar
• Mariani L, Miceli R, Michilin S, Gion M. Serial determination of CEA and CA 15.3 in breast cancer follow-up: an assessment of their diagnostic accuracy for the detection of tumour recurrences. Biomarkers 2009;14:130–136.
   PubMed Web of Science ®Google Scholar
• Nishimura R, Nagao K, Miyayama H, Matsuda M, Baba K, Matsuoka Y, Yamashita H. Elevated serum CA15-3 levels correlate with positive estrogen receptor and initial favorable outcome in patients who died from recurrent breast cancer. Breast Cancer 2003;10:220–227.
   PubMedGoogle Scholar
• Orciari S, Di Nuzzo S, Lazzarini R, Caprari P, Procopio A, Catalano A. The effects of insulin and insulin-like growth factors on tumor vascularization: new insights of insulin-like growth factor family in cancer. Curr Med Chem 2009;16:3931–3942.
   PubMed Web of Science ®Google Scholar
• Li L, Huang X, Huo K. IGFBP3 polymorphisms and risk of cancer: a meta-analysis. Mol Biol Rep 2010;37:127–140.
   PubMedGoogle Scholar
• Allen NE, Roddam AW, Allen DS, Fentiman IS, Dos Santos Silva I, Peto J, Holly JM, Key TJ. A prospective study of serum insulin-like growth factor-I (IGF-I), IGF-II, IGF-binding protein-3 and breast cancer risk. Br J Cancer 2005;92:1283–1287.
   PubMed Web of Science ®Google Scholar
• Fletcher O, Gibson L, Johnson N, Altmann DR, Holly JM, Ashworth A, Peto J, Silva Idos S. Polymorphisms and circulating levels in the insulin-like growth factor system and risk of breast cancer: a systematic review. Cancer Epidemiol Biomarkers Prev 2005;14:2–19.
   PubMed Web of Science ®Google Scholar
• Al-Delaimy WK, Flatt SW, Natarajan L, Laughlin GA, Rock CL, Gold EB, Caan BJ, et al. IGF1 and risk of additional breast cancer in the WHEL study. Endocr Relat Cancer 2011;18:235–244.
   PubMed Web of Science ®Google Scholar